



01-23-02

Express Mail No. EL 715381300 US  
Docket No. 20827 US (C38435/123864)JC978 U.S. PTO  
10/05/2002  
01/17/02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Werner BONRATH, et al.

)

Serial No.: Not Yet Assigned

)

Examiner: Unassigned

Filed: Herewith

)

Art Unit: Unassigned

For: **PROCESS FOR MAKING VITAMIN E  
USING HYDROGEN-  
TRIS(OXALATO) PHOSPHATE**

)

New York, NY  
January 17, 2002Box Patent Application  
Commissioner For Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the utility patent application of Inventors:

**Werner BONRATH, Thomas NETSCHER, and Ulrich WIETELMANN**For: **PROCESS FOR MAKING VITAMIN E USING HYDROGEN-TRIS(OXALATO)  
PHOSPHATE**

1.  The application has 19 pages (including 15 pp. of specification, 3 pp. of claims pages, and 1 p. of abstract).
2.  The declaration and power of attorney
  - a.  has been executed by all the inventors; or
  - b.  has not been executed by all the inventors. A signed declaration and power of attorney will be submitted in due course.
3.  \_\_\_\_ sheets of drawings (Figures \_ - \_) are enclosed.

- RECORDED  
BY FAX
4.  A Sequence Listing is part of this application.
- a.  A Sequence Listing in both paper and computer readable form (diskette) as required by 37 CFR 1.821 et seq. is enclosed.
  - b.  Upon information and belief, the content of the paper and computer readable Sequence Listing are the same. See, 37 CFR §§1.821(f).
5.  An associate power of attorney is enclosed.
6.  An assignment of the invention from the inventor(s) to Roche Vitamins AG (with Recordation Form Cover Sheet in duplicate), and an assignment from Roche Vitamins AG to Roche Vitamins Inc. (with Recordation Form Cover Sheet in duplicate). Please record the Assignment from the inventors to Roche Vitamins AG first, then record the assignment from Roche Vitamins AG to Roche Vitamins Inc. and return both to the undersigned. A duplicate copy of this paper is enclosed.
- a.  Two checks in the amount of \$40 are enclosed to cover the recording fee. See paragraph 10.c., below.
  - b.  Please charge the recording fee to our Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
7.  Priority is hereby claimed under 35 USC §119 based on EP Appln. No. 01101026.1, filed January 18, 2001 in Europe.
- a.  A certified copy of the priority document is enclosed.
  - b.  The certified priority document will follow.
8.  Priority is hereby claimed under 35 USC §119(e) based on provisional application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, in \_\_\_\_\_. Please amend the specification by inserting, before the first line, the following sentence: -- This application claims priority under 35 U.S.C. § 119(e) of provisional application Serial No \_\_\_\_\_, filed \_\_\_\_\_. --
9.  The filing fee is calculated below on the basis of the claims existing in the application plus or minus any claims added or canceled by amendment:

Claims as Filed, Plus/Minus Any Claims Added/Canceled By Amendment

For	Number Filed	Number Extra	Rate	Basic Fee =	\$ 740.00
Total claims	22 -20=	2	x \$18 =	\$	36.00
Independent claims	1 -3=	0	x \$84 =	\$	0.00
<b>Total Filing Fees</b>				<b>\$</b>	<b>776.00</b>

- a. [x] A check in the amount of \$776.00 to cover the filing fee is enclosed. If our check is missing or otherwise insufficient, or if any additional fees are required, please charge (or credit any overpayment) to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
- b. [ ] Please charge Deposit Account No. 02-4467 in the amount of \$\_\_\_\_\_. A duplicate copy of this paper is enclosed.
10. [x] The Commissioner is hereby authorized to charge payment of the following fees, or to credit any overpayment, to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
- a. [x] Any additional filing fees required under 37 CFR Section 1.16 not otherwise paid by check.
  - b. [x] Any patent application processing fees required under 37 CFR Section 1.17 not otherwise paid by check.
  - c. [x] Any additional Assignment recording fees under 37 CFR Section 1.21 (h) not otherwise paid by check.
11. [ ] A preliminary amendment is enclosed. Please enter it before calculating the filing fee.
12. [ ] An Information Disclosure Statement is enclosed.
13. [x] Address all communications to:

Stephen M. Haracz Esq.  
BRYAN CAVE LLP  
245 Park Avenue  
New York, NY 10167-0034  
tel. (212) 692-1800

Respectfully submitted,

By: 

Gonzalo Merino  
Registration No. P-51,192  
BRYAN CAVE LLP  
245 Park Avenue  
New York, NY 10167-0034  
(212) 692-1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Werner BONRATH, *et al.* )  
U.S. Serial No.: Not Yet Assigned ) Examiner: Unassigned  
Filing Date: Herewith ) Art Unit: Unassigned  
For: **PROCESS FOR MAKING VITAMIN E**  
**USING HYDROGEN-**  
**TRIS(OXALATO) PHOSPHATE**

**CERTIFICATE OF EXPRESS MAILING**


"Express Mail" Mailing Label No.: **EL 715 381 300 US**

Date of Deposit: January 17, 2002.

I hereby certify that the following:

- Certificate of Express Mailing (1 p);
- Transmittal letter (3 pp, in duplicate);
- Specification, Claims and Abstract (19 pp);
- Declaration and Power of Attorney (3 pp) (unexecuted);
- Transmittal of Priority Document Under 35 USC § 119 (1 p);
- Certified Copy of Priority Document (EP Appln. No. 01101026.1);
- Check for \$776.00; and
- Return postcard.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the Date of Deposit indicated above in an envelope addressed to Box PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.



\_\_\_\_\_  
Gregory Small  
Signature of Person Making Deposit

BRYAN CAVE LLP  
245 Park Avenue  
New York, New York 10167-0034  
(212) 692-1800